Provention Bio (PRVB) Releases Earnings Results
Provention Bio (NASDAQ:PRVB) issued its earnings results on Thursday. The company reported ($0.17) earnings per share (EPS) for the quarter, Morningstar.com reports.
Shares of PRVB traded down $0.02 during mid-day trading on Friday, reaching $3.16. The company had a trading volume of 21,053 shares, compared to its average volume of 51,935. Provention Bio has a twelve month low of $2.52 and a twelve month high of $8.00.
A hedge fund recently bought a new stake in Provention Bio stock. Dean Capital Investments Management LLC bought a new position in Provention Bio Inc (NASDAQ:PRVB) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 40,950 shares of the company’s stock, valued at approximately $164,000. Dean Capital Investments Management LLC owned approximately 0.12% of Provention Bio at the end of the most recent quarter.
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
Further Reading: What are no-load funds?
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.